Skip to content
Menu

Rapport Therapeutics, Inc. RAPP

Full chart Compare
Set alert

Price alert · RAPP

All alert types
23.16 USD -0.43 (-1.82%)

Regular-session close

23.16 0.00 0.00%

After hours · Nov 20, 4:26 PM ET

23.00 Day range 23.83
22.50 52-week range 52.50
YTD
-23.67%
1 year
-13.74%

5D -2.86 (-10.99%)

23242526MonTueWedThuFri23.16
Market cap
1.37B
Revenue (ttm)
20.00M
EPS (ttm)
-3.17
Shares out
59.28M
Forward P/E
-5.84
YTD return
-23.67%
1-year return
-13.74%
50-day average
30.26
200-day average
35.52
Enterprise value
1.01B
Volume
437.72K
Avg volume
785.98K
Open
23.23
Previous close
23.59
Day's range
23.00 – 23.83
52-week range
22.50 – 52.50
Beta
1.40
Analysts
Strong Buy
Price target
64.21 (+177.3%)
Earnings date
Mar 9, 2027

Key statistics

Price / sales
68.65
Price / book
2.85
Free cash flow
-75.28M
Total cash
395.03M
Total debt
9.39M
Return on equity
-33.33%
Short % of float
9.84%

Fundamental scorecard

3 of 25 checks passed on RAPP’s reported financials

ValueGrowthProfitabilityHealthDividend

3of 25 checks passed

  • Value 0 of 5
  • Growth 0 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
RAPP Revenue — quarterly 0
RAPP Net income — quarterly -40.23M
RAPP EPS — quarterly -0.84

Earnings

RAPP recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Mar 9, 2027Dec 30, 2026-0.87———
Nov 4, 2026Sep 30, 2026-1.18-0.84+0.34+28.81%
Aug 5, 2026Jun 30, 2026-0.96311-1.19-0.23-23.56%
May 7, 2026Mar 31, 2026-0.56-0.42+0.14+25.00%
Mar 10, 2026Dec 31, 2025-0.65-0.72-0.07-10.77%
Nov 6, 2025Sep 30, 2025-0.77-0.71+0.06+7.79%

Upgrades / downgrades

RAPP analyst upgrades and downgrades
DateFirmActionFromTo
Nov 5, 2026UBSmainBuyBuy
Nov 5, 2026GuggenheimmainBuyBuy
Nov 5, 2026Wells FargomainOverweightOverweight
Oct 21, 2026Jones TradingmainBuyBuy
Oct 21, 2026Wells FargomainOverweightOverweight
Oct 21, 2026GuggenheimmainBuyBuy

About Rapport Therapeutics, Inc.

Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. It also develops nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and migraine; and a9a10 nAChR for the treatment of hearing/vestibular disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on RAPP — it syncs with the Stock Master app.

Insider holders

RAPP insider holders
InsiderRelationLatest transactionDateShares held
BREDT DAVIDOfficerConversion of Exercise of derivative securityFeb 18, 2026393,075
CEESAY ABRAHAM NChief Executive OfficerSaleOct 6, 2026554,703
GAULT CHERYLChief Operating OfficerSaleSep 29, 2026139,914
HUBER REID M.DirectorPurchaseSep 11, 202520,400
IGNELZI TROY AChief Financial OfficerPurchaseOct 20, 202615,500
MARAGANORE JOHN MDirectorPurchaseOct 21, 20260

Institution ownership

RAPP institution ownership
Holder% heldSharesValueReported
FMR, LLC12.14%7,196,657166.67MSep 29, 2026
Trv Gp V, LLC 10.59%6,280,525145.46MSep 29, 2026
Arch Venture Management, Llc6.29%3,728,73886.36MSep 29, 2026
Goldman Sachs Group Inc5.02%2,973,79668.87MSep 29, 2026
Blackrock Inc.4.86%2,881,26466.73MSep 29, 2026
Capital International Investors4.48%2,653,64061.46MSep 29, 2026

Fund ownership

RAPP fund ownership
Holder% heldSharesValueReported
SmallCap World Fund Inc5.26%3,121,01272.28MSep 29, 2026
Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund3.92%2,324,78853.84MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund1.66%986,73022.85MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF1.34%793,82618.39MSep 29, 2026
Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund1.19%702,99516.28MSep 29, 2026
Fidelity Mt. Vernon Street Trust-Fidelity Series Growth Company Fund1.02%603,30613.97MSep 29, 2026